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Understanding the Role of ApoE Fragments in Alzheimer's Disease
Abstract

Alzheimer's disease (AD) is one of the most devastating neurodegenerative diseases. It has been known for
decades that the APOE ɛ4 allele is the most significant genetic risk factor for late-onset AD and yet its precise
role in the disease remains unclear. The APOE gene encodes apolipoprotein E (apoE), a 35 kDa glycoprotein
highly expressed in the brain. There are three different isoforms: apoE3 is the most common allele in the
population, whilst apoE2 decreases, and apoE4 increases AD risk. ApoE has numerous functions that affect
neuronal and non-neuronal cells, thus how it contributes to disease onset and progression is hotly debated.
The apoE4 isoform has been linked to the accumulation of both of the major pathological hallmarks of AD,
amyloid plaques containing amyloid β peptides, and neurofibrillary tangles containing hyperphosphorylated
tau protein, as well as other hallmarks of the disease, including inflammation and oxidative stress. Numerous
studies have shown that apoE undergoes fragmentation in the human brain, and that the fragmentation
pattern varies between isoforms. It was previously shown that apoE4 has neurotoxic functions, however recent
data has also identified a neuroprotective role for the apoE N-terminal 25 kDa fragment, which is more
prevalent in apoE3 individuals. The ability of the apoE 25 kDa fragment to promote neurite outgrowth was
recently demonstrated and this suggests there is a potential loss of neuroprotection in apoE4 individuals in
addition to the previously described gain of toxic function for specific apoE4 fragments. Here we review the
enzymes proposed to be responsible for apoE fragmentation, the specific functions of different apoE
fragments and their possible links with AD.
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Abstract
Alzheimer’s disease (AD) is one of the most devastating neurodegenerative diseases. It has been
known for decades that the APOE ɛ4 allele is the most significant genetic risk factor for late-onset AD
and yet its precise role in the disease remains unclear. The APOE gene encodes apolipoprotein E
(apoE), a 35 kDa glycoprotein highly expressed in the brain. There are three different isoforms: apoE3
is the most common allele in the population, whilst apoE2 decreases, and apoE4 increases AD risk.
ApoE has numerous functions that affect neuronal and non-neuronal cells, thus how it contributes to
disease onset and progression is hotly debated. The apoE4 isoform has been linked to the
accumulation of both of the major hallmarks of AD, amyloid β (Aβ) plaques and neurofibrillary
tangles (NFT), as well as other hallmarks of the disease, including inflammation and oxidative stress.
Numerous studies have shown that apoE undergoes fragmentation in the human brain, and that the
fragmentation pattern varies between isoforms. It was previously considered that apoE4 has
neurotoxic functions, however recent data has identified a neuroprotective role for the apoE Nterminal 25 kDa fragment, which is more prevalent in apoE3 individuals. The ability of the apoE 25
kDa fragment to promote neurite outgrowth was recently demonstrated and this suggests there is a
potential loss of neuroprotection in apoE4 individuals. Here we review the enzymes proposed to be
responsible for apoE fragmentation, the specific functions of different apoE fragments and their
possible links with AD.
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Introduction
Apolipoprotein E (apoE) is a 35-kDa glycoprotein widely expressed in the human body that functions
as a lipid transporter. Three different alleles of the APOE gene are present in the population: ɛ2, ɛ3
and ɛ4 , with frequencies of 6.4, 78.3 and 14.5%, respectively [1]. The ɛ4 allele is the major genetic
risk factor of late-onset AD, whilst ɛ2 protects against the disease [2]. The mechanisms by which
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APOE genotype influence AD onset and progression are incompletely understood. In the brain, apoE
is an extracellular protein that is expressed primarily by astrocytes and taken up by neurons; however,
under certain circumstances, apoE can also be expressed by microglia and neurons [3–5]. ApoE plays
a major role in the transport of cholesterol and other lipids, participating in their redistribution to cells
and facilitating their cellular uptake [5]. Moreover, in the brain apoE promotes Aβ clearance and
neuronal signalling [6].

ApoE structure and isoforms
The domain structure of apoE is composed of two main domains, with the N- and C-terminus, linked
by a hinge region (Fig. 1) [7, 8]. The N-terminal domain (residues 1-167) consists of a four alphahelix bundle with a region enriched in arginine and lysine residues (135-150) that forms the LDLreceptor binding region. The C-terminal domain (residues 206-299) consists of amphipathic alphahelices characteristic of the apolipoprotein family [9] and includes the lipid binding region (residues
244-272).
The three major alleles of the APOE gene found in the population give rise to six different genotypes:
the homozygotes ε2/2, ε3/3 and ε4/4, and the heterozygotes ε2/3, ε2/4 and ε3/4. The difference
between the three alleles is only two nucleotides, resulting in a protein change of two amino acids
located in positions 112 and 158. As shown in Fig., apoE2 contains Cys112 and Cys158, apoE3 Cys112
and Arg158 and apoE4 Arg112 and Arg158 [10]. This amino acid change within the isoforms leads to
differences in protein stability and interactions: by changing Cys112 into Arg112 in apoE4, the protein
loses the ionic association between Glu109 and Arg61, leaving Arg61 free to interact with Glu255, and
therefore creating an inter-domain interaction that reduces the lipid binding capacity of apoE4. In
apoE3 and apoE4 there is a salt-bridge between Arg158 and Asparagine (Asp)154 that is lost in apoE2
with Cys158. In this case there is a salt-bridge between Asp154 and Arg150 that removes the positive side
chain of Arg150 away from the LDL receptor binding region, affecting its binding capacity [11]. Due
to these amino acid interactions, the protein stability differs, with the apoE4 isoform the least stable,
followed by apoE3, while apoE2 is the most stable [12].
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The APOE ɛ4 allele is the major genetic risk factor of Alzheimer’s disease
The ɛ4 allele of the APOE gene is the major genetic risk factor of late onset AD [2]. Carriers of one
copy of the APOE ɛ4 are three times more likely to develop AD, and those that are homozygous for
the APOE ɛ4 have a ten times increased risk of developing the disease [13]. Moreover, the age of
onset is lower in the APOE ɛ4 AD population [13]. The exact mechanism by which apoE influences
AD remains unclear. Two of the major hallmarks of AD are the presence of extracellular deposition of
Aβ, forming amyloid plaques, and the intracellular presence of NFT, composed of aggregations of
hyperphosphorylated tau protein [14–17].
One hypothesis linking apoE and AD involves a direct interaction between apoE and Aβ peptides.
ApoE has been identified within Aβ plaques found in AD brains [18, 19], and other studies in vitro
have shown that the binding between apoE and Aβ occurs between residues 13-17 of the Aβ peptide
with residues 144-148 of the N-terminal region and residues 244-248 of the C-terminal region of apoE
[20, 21]. However, another in vitro study detected minimal levels of interaction between apoE and Aβ
using the physiological levels found in cerebrospinal fluid (Aβ:apoE molar ratio of 1:50-75), and
proposed instead that apoE influences Aβ metabolism via interaction with other transporters and
receptors in cells [22]. ApoE knock-out studies in mice have shown that apoE is necessary to initiate
and maintain Aβ plaques [23, 24], while another study reported that apoE decreases the initiation of
Aβ fibril formation [25]. Moreover, apoE4 has been shown to be less effective in the inhibition of Aβ
fibril formation than apoE3 [25, 26]. Even if the exact mechanism by which apoE interacts with Aβ
remains to be clarified, microglia could be a central player in mediating this interaction. Microglia
upregulate apoE under certain stress conditions, and they have been found surrounding Aβ plaques
[27]. Moreover, a recent study showed that apoE deficiency in mice reduced microglial activation
around Aβ plaques [28], which could result in a reduced ability to clear Aβ plaques from the brain.
Another hypothesis linking apoE with AD is the direct interaction between apoE and tau protein.
ApoE has been located in NFT mediated by tau [19]. Stable complexes between the microtubulebinding domain of tau and the LDL-receptor binding domain of apoE3, but not apoE4, have been
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shown in vitro [29]. Overexpression of human apoE4 in neurons of transgenic mice caused an
increase in tau hyperphosphorylation mediated by Erk activation [30, 31]. Moreover, apoE-deficient
mice show increased hyperphosphorylation of tau than control mice [32], which might indicate that
apoE3 protects tau from hyperphosphorylation. A more recent study using P301S tau mutant
transgenic mice on an apoE knock-out or knock-in background showed that apoE4 expression caused
more brain atrophy and neurodegeneration than apoE2 or apoE3, while apoE knock-out mice were
protected from these changes [33]. This paper also identified a role for microglia in relation to tau,
finding that the presence of the apoE4 background promoted microglial reactivity after
lipopolysaccharide treatment [33].

ApoE is proteolytically cleaved in the brain
Apolipoprotein E has been shown to be proteolytically cleaved in the human brain generating
truncated fragments. Unfortunately, not much is known regarding fragmentation of apoE2, and reports
on the mechanism of generation and the function of the fragments are inconsistent in the literature.
However it is evident that the apoE fragmentation pattern differs between the apoE3 and apoE4
isoforms [34], therefore understanding the function of the apoE fragments may be critical to
understanding the role of apoE in AD. There is a 50% reduction of the 25 kDa N-terminal fragment in
apoE4 compared to apoE3 brains [34]. When apoE3 or apoE4 was overexpressed specifically in either
neurons or astrocytes, there was no fragmentation of apoE when overexpressed in astrocytes and in
neurons there were fewer fragments of apoE4 than apoE3 [35]. This paper also identified that
fragmentation was specific to brain regions highly affected in AD, such as the neocortex or
hippocampus [35]. Although astrocytes are responsible for high levels of apoE expression, together
this data suggests that the enzyme responsible for fragmentation is specifically expressed by neurons
and that the fragments may have a role in disease onset or progression.
A number of enzymes have been proposed to be responsible for apoE fragmentation in different
studies (Table 1). Enzymes belonging to either the aspartic or the serine protease family have taken
most of the attention. The first study by Marques et al. showed that the serine protease, thrombin,
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generated a 22 kDa N-terminal apoE fragment that was neurotoxic to primary neurons [36].
Moreover, the 22 kDa fragment from the apoE4 isoform showed higher toxicity than the apoE3
fragment [37, 38]. However, the apoE fragmentation pattern generated in vitro by thrombin digestion
is different from the pattern observed in the human brain [34]. Cathepsin D, an aspartic protease, was
proposed by Zhou et al. to generate a 24 kDa apoE fragment that does correspond to the
fragmentation observed in the brain [39]. The apoE fragments and cathepsin D also colocalize with
the Aβ plaques and NFTs in post mortem human tissue [39]. A chymotrypsin-like serine protease was
proposed by Harris et al., supported by studies using the specific enzyme inhibitor α1antichymotrypsin [40, 41]. It was also shown that the C-terminal fragment of apoE4 formed with the
chymotrypsin-like protease, comprising amino acids 272-299, induces neuropathology and
behavioural deficits in transgenic mice overexpressing the fragment [40]. Most recently, hightemperature requirement serine protease A1 (HtrA1) was shown to induce fragmentation of apoE in
vitro, generating a fragment of 25 kDa, encompassing amino acids 1-195. HtrA1 was able to cleave
apoE4 faster and to a greater extent than apoE3 [42]. Of particular interest, recombinant HtrA1
generated apoE3 fragments, particularly a stable 25 kDa fragment [42], that is very similar to the
major apoE fragment detected in the human brain [34]. Moreover, inducing apoE expression in SK-NSH neuroblastoma cells with all-trans retinoic acid led to the formation of a 25 kDa N-terminal apoE
fragment, the formation of which was blocked by either HTRA1 knock-down or inhibition with the
specific HtrA1 boronic acid inhibitor [43]. These last two papers together suggest that HtrA1
expressed by neurons could be responsible for generating the 25 kDa N-terminal apoE fragment.
Table 1. Enzymes proposed to cleave apolipoprotein E.
Enzyme proposed

Fragment generated

Marques et al., 1996 [36]

Thrombin

ApoE 22 kDa N-terminal

Zhou et al., 2006 [39]

Cathepsin D

ApoE 24 kDa N-terminal
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Harris et al., 2003 [40]

Chymotrypsin-like protease

ApoE 272-299 C-terminal

HtrA1

ApoE 25 kDa N-terminal

Tamboli et al., 2014 [41]
Chu et al., 2016 [42]
Muñoz et al., 2018 [43]

Some studies have shown a brain homogenate pattern composed of one fragment detected at ~23-25
kDa and a smaller fragment detected at ~10 kDa [44]. The hinge region of apoE (that connects the Nterminal and C-terminal regions) is highly exposed, thus it is a likely potential target of enzyme
cleavage. Moreover, apoE4 has been shown to form a molten globule, in which the N-terminal region
is more open, and therefore more accessible to be cleaved by enzymes [45]. Predicted cleavage sites
for cathepsin D, chymotrypsin-like protease and HtrA1 are located throughout the amino acid
sequence of the protein, and specifically in the hinge region. These data also support the pattern seen
in the human brain, as the predicted molecular weight of the N-terminal domain is ~24 kDa and the Cterminal domain is ~10 kDa. Small variations in apoE molecular weight in different studies could be
due to a carbohydrate molecule attached to Thr194 via O-linked glycosylation [46].

Understanding the function of apoE fragments
The difference in the apoE fragmentation pattern observed in apoE3 and apoE4 brains leads us to
question the biological roles of the different apoE fragments and whether they have a relationship
with AD pathogenesis (Table 2). Specific apoE fragments have been directly linked with the
formation of Aβ plaques or NFT or the initiation of neurodegeneration [35, 40, 47–49]. An 18 kDa
N-terminal fragment (1-172 aa) of apoE4 was found within NFT of AD patients [50], however the
presence of this fragment in cerebrospinal fluid or plasma did not correlate with AD or APOE
genotype [51]. Huang et al. found a different fragment, 1-271 aa of apoE4, to be part of NFT-like
inclusions in neuronal cells [48]. Moreover, there was reduced truncation of apoE3 compared to
apoE4 and the inclusions did not occur in non-neuronal cells [48]. The same group generated a
transgenic mouse overexpressing the fragment 1-271 of apoE4. The mice that expressed high levels of
the fragment died at 2-4 months of age, showing AD-like neurodegeneration in the cortex and
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hippocampus. Meanwhile, the mice that expressed lower levels of the fragment showed impaired
learning and memory at 6-7 months of age [40]. Transgenic mice hAPPFAD [52] overexpressing apoE3
or apoE4 showed a decrease in Aβ deposition and increase of Aβ clearance compared to mice that did
not overexpress human apoE. However, the overexpression of the apoE4 1-271 fragment resulted in
lower binding to Aβ peptides than apoE3 or apoE4, suggesting there was a decrease in Aβ clearance
and an increase in Aβ deposition [53]. A similar fragment size was also tested in Neuro-2a mouse
neuroblastoma cells, showing that the 1-272 apoE4 fragment (including both LDL-receptor binding
and lipid binding regions) induced neurotoxicity and mitochondrial dysfunction, whereas the 1-240
fragment of apoE4 (containing only the LDL-receptor biding region) or full-length apoE4 did not
[54]. However, the 214-272 fragment of apoE4 (containing only the lipid-binding region) did not
induce neurotoxicity; this data therefore suggests a requirement for both regions of apoE4 to cause
mitochondrial dysfunction and neurotoxicity [54].
Other research groups have used mimetic peptides to address the function of specific fragments. The
apoE fragment 141-155 was shown to cause specific degeneration of neurites in embryonic chick
sympathetic neurons [55], whereas a shorter fragment, apoE 141-149, showed inhibition in
proliferation and cytotoxicity in IL2-dependent T lymphocytes [56]. Another peptide, apoE 133-149,
corresponding with the LDL-receptor binding region, was shown to be responsible for reducing
inflammation after injury. The peptide was able to mimic the effects of the full-length protein,
suppressing microglial activation and release of tumor necrosis factor-α and nitric oxide after
lipopolysachharide administration in BV2 mouse microglial cells [57, 58]. The same 133-149 apoE
peptide showed a neuroprotective function after exposure to N-methyl-D-aspartate, suppressing cell
death and calcium influx in primary neuronal-glia mixed cultures from brain cortices of fetal rats [59].
From the same group, the peptide was studied in mouse models of other disease models, including
multiple sclerosis and post-ischemia necrosis and also led to an improvement after administration of
the 133-149 apoE peptide [60, 61]. Another group used the same peptide apoE 133-149 to understand
its interaction with neuronal nicotinic acetylcholine receptors (nAChRs) [62–64]. There was a
complete inhibition of acetylcholine-evoked responses in rat hippocampal slices when the peptide was
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added. Furthermore, the same effect was seen when using the shorter peptide apoE 141-148, but not
with 133-140, demonstrating that the interaction with nAChR is mediated by the arginine-rich domain
[64]. Further studies in Xenopus laevis oocytes showed that the interaction of the apoE 133-149
peptide, or the shorter 141-148, disrupted nAChR signaling by blocking the α7 nAChRs [62, 63].
Isoform-specific proteolysis has been identified in a number of different studies, showing higher
levels of fragmentation of apoE4 compared to apoE3. A study in Neuro2a mouse neuroblastoma cells
identified an intracellular apoE C-terminal 13 kDa fragment following transfection with the human
apoE3 or apoE4. This fragment, that was highly expressed in apoE4-transfected cells, inhibited the
formation of Aβ fibrils and stabilized the formation of Aβ hexamers in vitro [65]. Other studies have
focused on the role of different N-terminal apoE4 fragments ranging from 17 to 22 kDa. Love et al.
suggested the extracellular proteases collagenase and matrix metalloprotease-9 produce a 17 kDa
apoE 1-151 fragment and in the apoE4 background the fragment traffics to the nucleus of BV2 mouse
microglial cells increasing cell death [49]. Dafnis et al. showed in the SK-N-SH human
neuroblastoma cell line that the 19 kDa N-terminal fragment of apoE4 (apoE 1-165) stimulated the
intracellular accumulation of Aβ42, generating ROS, but this effect was absent with apoE3 or with the
21 kDa fragment (apoE 1-185) [66, 67]. However, the 1-185 fragment of apoE4 promotes matrix
metalloprotease 9 / tissue inhibitor of metalloprotease 1 (MMP-9/TIMP1), induced by expression of
IL-1β in human neuroblastoma SK-N-SH cells and astrocytoma cells SW-1783 cells [68]. The 22 kDa
fragment proposed to be generated by thrombin cleavage exhibited neurotoxicity from apoE4 but not
when generated from apoE3 in primary neurons [36]. The same fragment was studied in embryonic
chick sympathetic ganglia and embryonic rat hippocampus tissue showing that the fragment generated
an increase in intracellular calcium and the neurotoxic function of the apoE4 fragment was mediated
through the heparan sulfate proteoglycan-LDL receptor-related protein complex [37, 38]. We recently
identified that the 25 kDa fragment generated by HtrA1 cleavage in the apoE3 background of SK-NSH human neuroblastoma cells was stable and induced neuritogenesis [43]. This suggests that the 25
kDa apoE fragment may also promote neurite outgrowth in vivo. Thus, the reduction of this 25 kDa
N-terminal fragment in apoE4 subjects could contribute to a reduction in neuritogenesis, in addition to
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the potential neurotoxic effects previously proposed for the apoE4 C-terminal fragments along with
other apoE peptides (Table 2).
Table 2. Proposed functions of apolipoprotein E fragments in cell and animal models related to AD and
differences in apoE isoforms.

Crutcher et al.,
1994 [55]

Clay et al., 1995
[56]

ApoE fragment

Function of the

studied

peptide

ApoE 141-155

ApoE 141-149

Causes neurite
degeneration

Model of study

Differences within
apoE isoforms

Embryonic chick
sympathetic ganglia

N/A

in vitro

Exhibits

IL2-dependent T

cytotoxicity

lymphocytes

N/A

Exhibits
Marques et al.,

ApoE 22 kDa

1996 [36]

N-terminal

cytotoxicity,
increased in apoE4

ApoE4 fragment
Primary neurons

background

has higher toxicity
than apoE3

compared to apoE3
The neurotoxic
Tolar et al., 1997

ApoE 22 kDa

function of the

[37]

N-terminal

fragment is
receptor-mediated

Tolar et al., 1999

ApoE 22 kDa

[38]

N-terminal

Huang et al., 2001

ApoE 1-271

[48]

N-terminal

Embryonic chick
sympathetic ganglia

ApoE4 fragment

in vitro and

showed higher

embryonic rat

toxicity than apoE3

hippocampal tissue

Induces calcium

Embryonic chick

influx and

sympathetic ganglia

neurotoxicity

in vitro and

involving cell

embryonic rat

surface receptors

hippocampal tissue

Induces NFT-like
inclusion in
neuronal cells

Neuro-2a mouse
neuroblastoma cells

Only apoE4 studied

ApoE4 showed
more inclusions
than apoE3

Suppresses
Laskowitz et al.,
2001 [57]

microglial
ApoE 133-149

activation and
release of TNFα

BV2 mouse
microglia cells

N/A

and NO
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Suppresses
Aono et al., 2003
[59]

neuronal cell death
ApoE 133-149

and calcium influx
associated with N-

Primary neuronalglia cells

N/A

methyl-D-aspartate
Causes AD-like

Transgenic mice

Harris et al., 2003

ApoE 1-271

neurodegeneration

C57BL6/J

[40]

N-terminal

and behavioural

overexpressing

deficits

apoE 1-271

Only apoE4 studied

Supresses
Lynch et al., 2003
[58]

ApoE 133-149

inflammatory

Wild-type mice

response after LPS

C57BL6/J

N/A

administration
Klein and Yakel,

ApoE 133-149

2004 [64]

ApoE 141-148

Inhibit Ach-evoked
responses in a dosedependent manner

Rat hippocampal
slices

N/A

Exhibits
Chang et al., 2005

ApoE 1-272

neurotoxicity via

Neuro-2a mouse

[54]

N-terminal

mitochondrial

neuroblastoma cells

Only apoE4 studied

dysfunction
Inhibits Aβ fibril
ApoE4 generates

formation and
Wellnitz et al.,

ApoE 13 kDa

induces formation

Neuro-2a mouse

more 13 kDa

2005 [65]

C-terminal

and stabilization of

neuroblastoma cells

fragment than

hexameric species

apoE2 or 3

of Aβ
Gay et al., 2006,

ApoE 133-149

2007 [62, 63]

ApoE 141-148

Block α7 nAChRs
disrupting nAChR
signalling

Xenopus laevis
oocytes

N/A

ApoE 1-165
ApoE 1-165
Dafnis et al., 2010,

19 kDa and apoE

2016 [66, 67]

1-185 21 kDa
N-terminal

stimulates the
intracellular
accumulation of
Aβ42 that generates

SK-N-SH human

Effects not seen in

neuroblastoma

apoE3

ROS, but apoE
1-185 do not

11

Full-length apoE3
Decreases Aβ

Transgenic mice

and apoE4

Bien-Ly et al.,

ApoE 1-271

clearance and

J20 line of hAPPFAD

expressing mice

2011 [53]

N-terminal

increases Aβ

and overexpressing

were able to

deposition

apoE 1-271

stimulate Aβ
clearance

Promotes
MMP9/TIMP1

SK-N-SH human

Dafnis et al., 2012

ApoE 1-185

imbalance by

neuroblastoma and

[68]

21 kDa N-terminal

inducing IL-1β and

SW-1783 human

reducing IL-10

astrocytoma cells

Only apoE4 studied

expression
Trafficking to the
Love et al., 2017

ApoE 1-151

nucleus and

BV2 mouse

Effects not seen in

[49]

17 kDa N-terminal

increase in cell

microglia cells

apoE3

death
Muñoz et al., 2018

ApoE 1-195

Promotes

[43]

25 kDa N-terminal

neuritogenesis

SK-N-SH / SHSY5Y human

Only apoE3 studied

neuroblastoma cells

Conclusions
Since the APOE ɛ4 allele is the major genetic risk factor for AD, understanding its role in the
development of AD is paramount. A direct link between apoE and the two major hallmarks of the
disease, Aβ plaques and NFTs, has been identified but the precise roles that apoE plays in AD are still
debated. ApoE is expressed in the brain mainly by astrocytes, however the evidence suggests that
neurons rather than astrocytes express the enzymes leading to apoE fragmentation. A number of
enzymes have been proposed to cleave apoE, whilst different fragments have been shown to have
diverse effects on cells. The majority of studies have focused on the toxic impact of apoE4 (reviewed
[69]) promoting neurotoxicity [36], mitochondrial dysfunction [54], NFT-like inclusions [48],
neurodegeneration [40], cell death [49] or suppressing microglial activation [57] (Fig. 2). However,
our recent study has found a protective function of the apoE 25 kDa fragment that is more prevalent in
apoE3 than apoE4 brains [43]. This suggests that in addition to the neurotoxic effects of apoE4
fragments, a loss of neuroprotective apoE3 fragments may also contribute to neurodegeneration in
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AD. Future studies need to address the role of apoE fragments in astrocytes, microglia and other nonneuronal cell types and their precise role in AD pathogenesis. Very little is known about the
fragmentation of apoE2 and this should be investigated in the future. Understanding the differences
between apoE isoforms in different cell types will undoubtedly involve the use of induced pluripotent
stem cells (iPSCs) that express physiological levels of endogenous genes, rather than relying on
overexpression models. In particular the use of genome-edited isogenic lines [70] bearing
apoE2/apoE3/apoE4 can delineate the specific effects of endogenous levels of apoE fragments from
each genotype and their role in AD pathogenesis.

Figure legends
Fig. 1 Structure of apolipoprotein E. The N-terminal domain (1-167 aa) is connected by a hinge
region with the C-terminal domain (206-299 aa). The LDL-receptor binding (135-150 aa) and the
lipid binding (244-272) regions are shown. Positions 112 and 158 show the different amino acids that
give rise to each of the apoE isoforms (ɛ2, ɛ3 and ɛ4).

Fig. 2 Overview of apoE structure and the function assigned to each of the fragments studied.
Red fragment, apoE4; blue fragment, apoE3; black fragment, N/A.
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Fig. 1
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Fig. 2
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